Roche already has one Alzheimer’s candidate in its pipeline targeting tau, but has added a second via a deal with Belgian drugmaker UCB worth up to $2 billion. The Swiss pharma group is paying $ ...
Belgian biopharma UCB has been given the green light by the FDA for Zilbrysq as a treatment for generalised myasthenia gravis (gMG), one of two drugs that the company hopes will shake up the ...
Clobazam is the first and only 1,5-benzodiazepine in clinical use as an anticonvulsant. Clobazam exerts it anticonvulsant effects via its selective affinity for the ω 2 site of the GABA-A ...
Copyright © 2025 MarketWatch, Inc. All rights reserved.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback